Your browser doesn't support javascript.
loading
A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer.
Liu, Junquan; Chiang, Huai-Chin; Xiong, Wei; Laurent, Victor; Griffiths, Samuel C; Dülfer, Jasmin; Deng, Hui; Sun, Xiujie; Yin, Y Whitney; Li, Wenliang; Audoly, Laurent P; An, Zhiqiang; Schürpf, Thomas; Li, Rong; Zhang, Ningyan.
Afiliación
  • Liu J; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Chiang HC; Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, DC, USA.
  • Xiong W; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Laurent V; Evotec (France) SAS, Campus Curie, 195 route d'Espagne, 31036 Toulouse CEDEX, Toulouse, France.
  • Griffiths SC; Evotec (UK) Ltd, Abingdon, UK.
  • Dülfer J; Evotec SE, Manfred Eigen Campus, Hamburg, Germany.
  • Deng H; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Sun X; Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, DC, USA.
  • Yin YW; Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, Texas, USA.
  • Li W; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Audoly LP; Parthenon Therapeutics Inc, Boston, Massachusetts, USA.
  • An Z; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA Zhiqiang.An@uth.tmc.edu Thomas.schuerpf@parthenontx.com rli69@gwu.edu Ningyan.Zhang@uth.tmc.edu.
  • Schürpf T; Parthenon Therapeutics Inc, Boston, Massachusetts, USA Zhiqiang.An@uth.tmc.edu Thomas.schuerpf@parthenontx.com rli69@gwu.edu Ningyan.Zhang@uth.tmc.edu.
  • Li R; Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, DC, USA Zhiqiang.An@uth.tmc.edu Thomas.schuerpf@parthenontx.com rli69@gwu.edu Ningyan.Zhang@uth.tmc.edu.
  • Zhang N; Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA Zhiqiang.An@uth.tmc.edu Thomas.schuerpf@parthenontx.com rli69@gwu.edu Ningyan.Zhang@uth.tmc.edu.
J Immunother Cancer ; 11(6)2023 06.
Article en En | MEDLINE | ID: mdl-37328286
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor con Dominio Discoidina 1 / Anticuerpos Monoclonales / Neoplasias Límite: Animals Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Receptor con Dominio Discoidina 1 / Anticuerpos Monoclonales / Neoplasias Límite: Animals Idioma: En Revista: J Immunother Cancer Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido